Bulletin
Investor Alert

New York Markets Close in:

press release

April 14, 2022, 9:04 a.m. EDT

BeyondSpring Files 2021 Annual Report on Form 20-F

NEW YORK, April 14, Apr 14, 2022 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") /zigman2/quotes/204570570/composite BYSI +3.28% , a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission ("SEC") on April 14, 2022. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section.

The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring's first-in-class lead asset, Plinabulin, is being developed as a "pipeline in a drug" in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). The Plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the Plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2 [nd] /3 [rd] line NSCLC (EGFR wild type). Additionally, Plinabulin is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. In addition to Plinabulin, BeyondSpring's pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

COMTEX_405700174/2471/2022-04-14T09:04:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/204570570/composite
US : U.S.: Nasdaq
$ 1.61
+0.05 +3.28%
Volume: 265,101
July 5, 2022 3:44p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$60.73 million
Rev. per Employee
$17,776
loading...

Partner Center

Link to MarketWatch's Slice.